Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: An immunohistochemical study

Applied Immunohistochemistry and Molecular Morphology

Volumn 12, Issue 4, 2004, Pages 338-341

  Kelley, Todd W ^a   Borden, Ernest C ^b   Goldblum, John R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Estrogen receptor; Leiomyosarcoma; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR; FORMALDEHYDE; PARAFFIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEIOMYOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; TUMOR LOCALIZATION; UTERUS; UTERUS LEIOMYOSARCOMA;

EID: 10044260864     PISSN: 15412016     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129039-200412000-00008     Document Type: Article

References (13)

1. Gustafson P, Willen H, Baldetorp B, et al. Soft tissue leiomyosarcoma: a population-based epidemiologic and prognostic study of 48 patients including cellular DNA content. Cancer. 1992;70:114-119.
2. Jensen ML, Jensen OM, Michalski W, et al. Intradermal and subcutaneous leiomyosarcoma: a clinicopathologic and immunohistochemical study of 41 cases. J Cutan Pathol. 1996;23:458-463.
3. Farshid G, Pradhan M, Goldblum J, et al. Leiomyosarcoma of somatic soft tissues: a tumor of vascular origin with multivariate analysis of outcome in 42 cases. Am J Surg Pathol. 2002;26:14-24.
4. Dzsinich C, Gloviczki P, van Heerden J, et al. Primary venous leiomyosarcoma: a rare but lethal disease. J Vasc Surg. 1992;15:595-603.
5. Zhai YL, Nikaido T, Shiozawa A, et al. Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus. Br J Cancer. 1999;80:1658-1664.
6. Amant F, de la Rey M, Dorfling CM, et al. PTEN mutations in uterine sarcomas. Gynecol Oncol. 2002;85:165-169.
7. Zhai YL, Nikaido T, Orii A, et al. Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma. Gynecol Oncol. 1999;75:453-459.
8. Rao UNM, Finkelstein SD, Jones MW. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas. Mod Pathol. 1999;12:1001-1009.
9. Hall KL, Teneriello MG, Taylor RR, et al. Analysis of Ki-Ras, p53 and MDM2 genes in uterine leiomyomas and leiomyosarcomas. Gynecol Oncol. 1997;65:330-335.
10. Lau TK, Wong WS. Uterine leiomyosarcoma associated with pregnancy: report of two cases. Gynecol Oncol. 1994;53:245-247.
11. Kokawa K, Yamoto M, Yata C, et al. Postmenopausal intravenous leiomyomatosis with high levels of estradiol and estrogen receptor. Obstet Gynecol. 2002;100:1124-1126.
12. Bodner K, Bodner-Adler B, Kimberger O, et al. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res. 2003;23:729-732.
13. Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol. 2001;32:984-987.